Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.

                               NOVAVAX, INC.
                 CONSOLIDATED STATEMENT OF OPERATIONS
          (in thousands, except per share and per share information)

                                                              Unaudited
                                                           Three-month ended
                                                         March 31,  March 31,
                                                           2009       2008
     Revenues:
         Total revenues                                     $21         458

     Operating costs and expenses:
       Research and development                           4,266       4,434
       General and administrative                         2,892       3,244

         Total operating costs and expenses               7,158       7,678

     Loss from continuing operations before interest     (7,137)     (7,220)
     Interest income, (loss), net                        (1,212)        117

     Loss from continuing operations                     (8,349)     (7,103)
     Loss from discontinued operations                        -        (652)

     Net loss                                            (8,349)     (7,755)

     Basic and diluted weighted average
       number of common shares used in
       computing basic net loss per share            68,692,455  61,280,155

     Basic and diluted net loss per share
       Loss per share from continuing operations         $(0.12)     $(0.12)
        Loss 
'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by ... Systems, Table-top Counters) by End-user (Inpatient Pharmacy Automation, ... to 2019” analyzes and studies the major market ... Asia-Pacific, and the Rest of the World (RoW). ... spread through 300 pages and in-depth TOC on ...
(Date:10/20/2014)... , A major pan-European survey into the ... care has revealed changing trends in many important GI ... of healthcare services across the continent. The results of ... (UEG), have been announced today and led to calls ... of GI disorders across Europe ...
(Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy ... of donor stem cells for dogs with osteoarthritis. Dr. ... has performed clinical stem cell therapy for 7 years. ... if a single injection of donor stem cells into ... pain and inflammation in the treated joints. , ...
(Date:10/19/2014)... The Asian Automatic patient billing report ... and forecast of revenue. The Automatic patient billing market ... million by 2018, at a developing CAGR of 7.2% ... of the Asian Automatic patient billing market, to get ... provides a glimpse of the segmentation of this market ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... Turn Massive Amounts of Data into Gems of Knowledge ... , Abstract , This paper discusses key ... the degree (volume) and complexity of life science data ... to data integration that enables rapid ‘harvesting’ and analysis ...
... Rönn 1 , M. Landström 2 , A. Edman-Örlefors 1 , and S. ... 1 GE Healthcare, Uppsala, Sweden , ... , , ... levels, with linearity over 3.6 orders of magnitude. Two antigens can be detected ...
... , Introduction , ... is a major requirement in drug development and a key ... coupled receptors (GPCRs) (1). , <P ,>It ... potential therapeutic value requiring identification of natural or artificial ligands. ...
Cached Biology Technology:Exploiting the Life Science Data Explosion to Speed New Drug Discovery 2Exploiting the Life Science Data Explosion to Speed New Drug Discovery 3Exploiting the Life Science Data Explosion to Speed New Drug Discovery 4Exploiting the Life Science Data Explosion to Speed New Drug Discovery 5Exploiting the Life Science Data Explosion to Speed New Drug Discovery 6Exploiting the Life Science Data Explosion to Speed New Drug Discovery 7Exploiting the Life Science Data Explosion to Speed New Drug Discovery 8Exploiting the Life Science Data Explosion to Speed New Drug Discovery 9Exploiting the Life Science Data Explosion to Speed New Drug Discovery 10Exploiting the Life Science Data Explosion to Speed New Drug Discovery 11Exploiting the Life Science Data Explosion to Speed New Drug Discovery 12Exploiting the Life Science Data Explosion to Speed New Drug Discovery 13Exploiting the Life Science Data Explosion to Speed New Drug Discovery 14Exploiting the Life Science Data Explosion to Speed New Drug Discovery 15Exploiting the Life Science Data Explosion to Speed New Drug Discovery 16Exploiting the Life Science Data Explosion to Speed New Drug Discovery 17Detection and quantitation of low-abundant proteins with ECL Plex fluorescent Western blotting 2Detection and quantitation of low-abundant proteins with ECL Plex fluorescent Western blotting 3Screening for β2-adrenergic receptor agonists using the pH-sensitive dye,CypHer5, and the IN Cell Analyzer 3000 2Screening for β2-adrenergic receptor agonists using the pH-sensitive dye,CypHer5, and the IN Cell Analyzer 3000 3Screening for β2-adrenergic receptor agonists using the pH-sensitive dye,CypHer5, and the IN Cell Analyzer 3000 4Screening for β2-adrenergic receptor agonists using the pH-sensitive dye,CypHer5, and the IN Cell Analyzer 3000 5Screening for β2-adrenergic receptor agonists using the pH-sensitive dye,CypHer5, and the IN Cell Analyzer 3000 6
(Date:10/19/2014)... access in India over the last 30 years ... emissions growth during that time, according to a ... Climate Change ., "Energy access is fundamental to ... life, including education, communication, and health," says IIASA ... While increased energy access is widely agreed to ...
(Date:10/17/2014)... – Accurate knowledge regarding Ebola is critical and pertinent ... of hazardous global outbreak and epidemic. The Journal, ... a special issue, Ebola Virus and Public Health, to ... knowledge in this critical societal moment. , On ... Ebola for Clinicians . The primer was prepared by ...
(Date:10/16/2014)... on the human body. Battles are won, lost ... cancer, this stalemate—known as tumor dormancy—can last up ... phenomena that is poorly understood. , A ... Salvatore Torquato, a Professor of Chemistry at Princeton ... dormancy and the switch to a malignant state. ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Modeling tumor dormancy 2
... October, 2010 Elsevier Properties SA today congratulated ... (Sandy) Lawson, for receiving the 2011 Herman Skolnik ... Division of Chemical Information (CINF), the award recognizes ... and practice of chemical information science and related ...
... of cell and developmental biology, has been awarded one ... Awards, one of the NIH,s most prestigious grants. ... address a significant medical science challenge: identifying the full ... and disease processes such as cancer. Major, a ...
... Rensselaer Polytechnic Institute professors have been named 2010 fellows ... Center for Biotechnology and Interdisciplinary Studies (CBIS) and the ... Engineering Jonathan Dordick and Professor Emeritus of Chemistry Leonard ... "outstanding achievements in and contributions to the science, the ...
Cached Biology News:Professor Dr. Alexander (Sandy) Lawson is awarded the 2011 Herman Skolnik Award 2UNC scientist receives NIH director's New Innovator Award 2Rensselaer professors Dordick and Interrante named ACS Fellows 2
This kit only detects beta-galactosidase activity at pH 6 in cultured cells andtissue sections. Beta-galactosidase activity at pH 6 ispresent only in senescent cells, and is not found inpresenescent...
2,4,6, Trinitrophenyl hapten is conjugated to lipopolysaccharide (LPS)....
... need to make your strain of cells competent ... for preparing competent cells are comprehensive and customized ... service offers: High transformation efficiencies ... Quality control performance testing Great ...
... petroleum-based applications. Multiple solvents can be used, such as water, benzene, formamide, nitrobenzene, cyclohexane, 1,4-dioxane, ... * Range: ... ... ...
Biology Products: